News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
387,883 Results
Type
Article (18591)
Company Profile (124)
Press Release (369168)
Section
Business (120869)
Career Advice (704)
Deals (23565)
Drug Delivery (73)
Drug Development (56173)
Employer Resources (67)
FDA (9760)
Job Trends (8543)
News (214011)
Policy (19836)
Tag
Academia (896)
Alliances (29923)
Alzheimer's disease (725)
Approvals (9721)
Artificial intelligence (78)
Bankruptcy (218)
Best Places to Work (6485)
Biotechnology (57)
Breast cancer (63)
Cancer (593)
Cardiovascular disease (53)
Career advice (616)
Cell therapy (122)
Clinical research (45705)
Collaboration (195)
Compensation (72)
COVID-19 (1173)
C-suite (55)
Data (637)
Diabetes (88)
Diagnostics (2970)
Drug pricing (68)
Earnings (49728)
Employer resources (58)
Events (55556)
Executive appointments (169)
FDA (10053)
Funding (159)
Gene therapy (104)
GLP-1 (349)
Government (2086)
Healthcare (8237)
Infectious disease (1210)
Inflammatory bowel disease (69)
Interviews (97)
IPO (10721)
Job creations (2311)
Job search strategy (551)
Layoffs (189)
Legal (4368)
Lung cancer (99)
Manufacturing (106)
Medical device (5354)
Medtech (5357)
Mergers & acquisitions (12894)
Metabolic disorders (240)
Neuroscience (882)
NextGen Class of 2024 (2671)
Non-profit (1199)
Northern California (754)
Obesity (140)
Opinion (139)
Patents (73)
People (34476)
Pharmaceutical (66)
Phase I (13718)
Phase II (20044)
Phase III (15647)
Pipeline (166)
Policy (50)
Postmarket research (1640)
Preclinical (5364)
Radiopharmaceuticals (163)
Rare diseases (118)
Real estate (3172)
Regulatory (14101)
Research institute (941)
Resumes & cover letters (89)
Southern California (686)
Startups (1982)
United States (7161)
Vaccines (191)
Weight loss (109)
Date
Today (182)
Last 7 days (532)
Last 30 days (1933)
Last 365 days (23478)
2024 (19948)
2023 (26079)
2022 (33043)
2021 (34274)
2020 (32187)
2019 (23606)
2018 (17975)
2017 (20129)
2016 (18370)
2015 (22004)
2014 (16825)
2013 (13797)
2012 (14600)
2011 (15378)
2010 (14158)
Location
Africa (418)
Arizona (63)
Asia (27788)
Australia (5609)
California (1670)
Canada (848)
China (145)
Colorado (74)
Connecticut (82)
Europe (53248)
Florida (246)
Illinois (152)
Indiana (113)
Kansas (58)
Maryland (261)
Massachusetts (1409)
Minnesota (92)
New Jersey (625)
New York (561)
North Carolina (422)
Northern California (754)
Ohio (60)
Pennsylvania (501)
South America (662)
Southern California (686)
Texas (250)
Washington State (249)
387,883 Results for "telix pharmaceuticals limited".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Telix Pharmaceuticals Limited completes the acquisition of ARTMS, Inc.
ARTMS Inc. (ARTMS) is pleased to announce that the acquisition by Telix Pharmaceuticals Limited (Telix) has been completed.
April 11, 2024
·
3 min read
Deals
Telix Announces Launch of Proposed Initial Public Offering in the United States
Telix Pharmaceuticals Limited (the “Company” or “Telix”) today announces the launch of its initial public offering in the United States (the “Offering”) of 17,000,000 American Depositary Shares (“ADSs”), each representing one ordinary share in Telix.
June 5, 2024
·
6 min read
Telix Submits NDA for New Prostate Cancer Imaging Agent
Telix Pharmaceuticals Limited announces it has submitted a New Drug Application to the United States Food and Drug Administration for TLX007-CDx, a new and proprietary cold kit for the preparation of PSMA-PET imaging1 for prostate cancer.
May 28, 2024
·
7 min read
Deals
Telix Files Registration Statement for Proposed Initial Public Offering in the United States
Telix Pharmaceuticals Limited announces that it has filed a registration statement on Form F-1 with the United States Securities and Exchange Commission relating to a proposed initial public offering of its American Depository Shares, representing the Company’s ordinary shares, in the U.S. Telix has applied to list the ADSs on the Nasdaq Global Market under the symbol “TLX”.
May 17, 2024
·
5 min read
Deals
QSAM Biosciences Signs Definitive Agreement to be Acquired by Telix Pharmaceuticals
QSAM Biosciences Inc. (OTCQB: QSAM) (“QSAM or the “Company”) has signed a definitive Agreement and Plan of Merger (the “Agreement”) providing for the acquisition of the Company by Telix Pharmaceuticals Limited (ASX: TLX) (“Telix”).
February 7, 2024
·
8 min read
Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer
Telix Pharmaceuticals Limited announces the successful completion of CUPID1, a first-in-human Phase I dose escalation study of TLX592 in patients with advanced prostate cancer.
May 20, 2024
·
7 min read
Telix Completes TLX250-CDx (Zircaix™) BLA Submission for Kidney Cancer Imaging
Telix Pharmaceuticals Limited announces that it has completed the submission of a Biologics License Application to the United States Food and Drug Administration for its investigational radiodiagnostic PET1 agent, TLX250-CDx, for the characterisation of renal masses as clear cell renal cell carcinoma.
June 2, 2024
·
7 min read
Press Releases
Health Canada Approves Label Expansion for Telix’s Illuccix® to Include Patient Selection for PSMA-Targeted Therapy
October 7, 2024
·
7 min read
Press Releases
Telix Spins Off Rhine Pharma™ to Expand Global Access to Radiopharmaceuticals
October 22, 2024
·
8 min read
Telix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC Therapy Candidate in Prostate Cancer
Telix Pharmaceuticals Limited today announces additional positive data from the ProstACT SELECT trial (“SELECT”) of TLX591 (177Lu rosopatamab tetraxetan), a lutetium-labelled rADC therapy for the treatment of adult patients with PSMA-positive metastatic castrate-resistant prostate cancer (mCRPC).
May 30, 2024
·
9 min read
1 of 38,789
Next